Hepatitis B Virus Core Antigen (HBcAg) antibody (Cy5.5)

Catalog No. ABIN722996

The Mouse Monoclonal anti- antibody has been validated for IF (p). It is suitable to detect in samples from Hepatitis B Virus (HBV) and Virus.

Quick Overview for Hepatitis B Virus Core Antigen (HBcAg) antibody (Cy5.5) (ABIN722996)

Target: Hepatitis B Virus Core Antigen (HBcAg)

Reactivity: Hepatitis B Virus (HBV), Virus

Host: Mouse

Clonality: Monoclonal

Conjugate: Cy5.5

Application: Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Clone: 1H8

Product Details

Cross-Reactivity: Virus

Cross-Reactivity (Details): Hepatitis B Virus

Purification: Purified by Protein G.

Immunogen: Recombinant Hepatitis B Core Antigen (rHBcAg)

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: Hepatitis B Virus Core Antigen (HBcAg)

Alternative Name: HBcAg

Target Type: Viral Protein

Background:

Synonyms: C, Capsid protein, Core and e antigen, Core antigen, Core antigen, Core protein, HBc, HBcAg, HBVgp4, Hepatitis B Virus core antigen, p21.5, precore/core protein, CAPSD_HBVA3.

Background: Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection.The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.